logo

Drugs For Schistosomiasis Market

  • Industries
    •   Information & Technology
    •   Healthcare
    •   Machinery & Equipment
    •   Automotive & Transportation
    •   Food & Beverages
    •   Energy & Power
    •   Aerospace & Defense
    •   Agriculture
    •   Chemicals & Materials
    •   Architecture
    •   Consumer Goods
  • Blogs
  • About
  • Contact
  1. Home
  2. Healthcare
  3. Drugs For Schistosomiasis Market

Drugs For Schistosomiasis Market Size, Share, Growth, and Industry Analysis, By Types (Oxamniquine, Praziquantel, Others) , Applications (S. intercalatum, S. mekongi, S. japonicum, S. mansoni, S. haematobium) and Regional Insights and Forecast to 2032

 Request a FREE Sample PDF
Last Updated: May 19 , 2025
Base Year: 2024
Historical Data: 2020-2023
No of Pages: 114
SKU ID: 23594971
  •  Request a FREE Sample PDF
  • Summary
  • TOC
  • Drivers & Opportunity
  • Segmentation
  • Regional Outlook
  • Key Players
  • Methodology
  • FAQ
  •  Request a FREE Sample PDF

Drugs for schistosomiasis market Size

The Global drugs for schistosomiasis market was valued at USD 83.29 million in 2023 and is projected to reach USD 88.95 million in 2024, with substantial growth expected to USD 150.41 million by 2032, exhibiting a CAGR of 6.79% during the forecast period [2024-2032].

The US drugs for schistosomiasis market is expected to play a crucial role in this growth, driven by increasing awareness about the disease and expanding research and development in treatments. Schistosomiasis, a parasitic infection prevalent in tropical and subtropical regions, continues to drive demand for effective medications, with the need for novel treatments and improved therapeutic outcomes becoming more critical. 

Drugs For Schistosomiasis Market

Request a Free sample    to learn more about this report.

Drugs For Schistosomiasis Market Growth

The global Drugs for Schistosomiasis market has been experiencing significant growth, driven by increasing awareness about the disease, rising healthcare investments, and technological advancements in drug formulations. Schistosomiasis, a parasitic disease caused by Schistosoma worms, affects millions worldwide, particularly in regions like Sub-Saharan Africa, Southeast Asia, and Latin America. This widespread prevalence, coupled with the need for effective treatment solutions, has been a major factor contributing to the market's expansion. 

In addition to expanding access to existing drugs like praziquantel, innovations in the pharmaceutical industry have resulted in the development of combination therapies and drug alternatives. This trend has increased the scope for growth in both developed and developing countries. Research into vaccines and novel therapeutic agents has also gained momentum, positioning the market for long-term growth. 

Market growth is also driven by the rising burden of Schistosomiasis, particularly in rural and underdeveloped regions where healthcare infrastructure is often limited. The global push for universal health coverage and the integration of Schistosomiasis control programs into national health strategies are expected to further boost market demand. The increasing focus on preventive treatments, early diagnosis, and better patient adherence to prescribed therapies plays a crucial role in the market’s trajectory. 

Drugs For Schistosomiasis Market Trends

The Drugs for Schistosomiasis market is witnessing several key trends, shaped by both demand and technological advancements in the healthcare sector. One prominent trend is the shift towards combination therapies. With increasing drug resistance, particularly to praziquantel, researchers are exploring combination treatments that integrate multiple therapeutic agents to improve efficacy and reduce the likelihood of resistance development. 

Another trend is the growing collaboration between pharmaceutical companies and global health organizations. By teaming up with entities such as the World Health Organization (WHO) and various NGOs, these companies are ensuring that Schistosomiasis treatment reaches the most affected areas. Public-private partnerships are becoming more common, enabling faster development and distribution of drugs in endemic regions. 

Advances in drug formulations and delivery methods are also transforming the market. For instance, sustained-release formulations and oral tablets with improved taste profiles are expected to enhance patient compliance, particularly in pediatric and elderly populations. In parallel, researchers are exploring the potential of new drug classes, such as monoclonal antibodies and gene therapy, to combat Schistosomiasis more effectively. As these trends continue to evolve, the market will likely witness an ongoing shift toward more specialized and sustainable treatments for the disease.

Drugs For Schistosomiasis Market Dynamics

Drivers of Market Growth

Several key factors are driving the growth of the Drugs for Schistosomiasis market. One of the primary drivers is the increasing prevalence of Schistosomiasis in endemic regions, particularly in Sub-Saharan Africa, Southeast Asia, and parts of Latin America. As more individuals are diagnosed with the disease, the demand for effective treatments continues to rise, fueling market expansion. The burden of Schistosomiasis on public health systems has made it a priority for global health organizations, which in turn has resulted in greater focus on providing access to affordable and effective treatments.

Additionally, the increasing recognition of neglected tropical diseases (NTDs) and the rising funding from international organizations, governments, and private stakeholders have contributed to the market’s expansion. Programs aimed at controlling Schistosomiasis through mass drug administration (MDA) campaigns and improving healthcare infrastructure in endemic regions are also playing a critical role in boosting market demand.

Moreover, advancements in digital health technologies, such as mobile apps for treatment adherence and diagnostic tools, are contributing to improved disease management, further accelerating market growth.

Market Restraints

While the Drugs for Schistosomiasis market has experienced substantial growth, several factors restrain its full potential. One significant restraint is the limited access to healthcare infrastructure in rural and impoverished regions, which are the hardest-hit by Schistosomiasis. These areas often lack sufficient medical facilities and trained personnel to diagnose and treat the disease efficiently. 

Another challenge is the growing issue of drug resistance. Praziquantel, the most widely used treatment for Schistosomiasis, has seen increasing cases of resistance, making it less effective over time. This resistance has led to a greater demand for novel therapeutic agents, but the development of these alternatives is costly and time-consuming. Regulatory hurdles can also slow down the approval and availability of new drugs, further delaying access to more effective treatments.

Additionally, the lack of a comprehensive vaccine for Schistosomiasis presents another limitation. Vaccine development is a complex and lengthy process, and until one is approved, the market will continue to rely heavily on pharmaceutical treatments. The challenge of ensuring consistent drug supply and the potential for counterfeit drugs in developing countries also impacts market growth, as it compromises patient outcomes and treatment adherence.

Market Opportunities

The Drugs for Schistosomiasis market holds significant opportunities, particularly in regions where the disease is most prevalent. One major opportunity lies in the increasing focus on neglected tropical diseases (NTDs) by international organizations and governments. With rising awareness and funding for NTD programs, there is growing support for Schistosomiasis treatment initiatives. This increased investment presents an opportunity for pharmaceutical companies to partner with global health organizations to expand their market reach and improve access to life-saving treatments in endemic regions.

The demand for more effective and affordable treatments creates a significant opportunity for innovation. Pharmaceutical companies can invest in the development of new drug classes, such as monoclonal antibodies, or explore combination therapies that reduce drug resistance. The growing interest in precision medicine also presents an opportunity for personalized treatment options tailored to the genetic profile of patients, improving treatment efficacy and reducing side effects.

The expansion of healthcare infrastructure in developing regions also presents an opportunity for market growth. Governments and international organizations are increasingly investing in building healthcare systems that can better diagnose and treat Schistosomiasis, thereby improving access to essential drugs. Furthermore, the rising awareness of Schistosomiasis as a public health issue is likely to encourage more funding and research into new therapeutic solutions.

Market Challenges

The Drugs for Schistosomiasis market faces several challenges that could hinder its growth and development. One of the primary challenges is the slow progress in vaccine development. Despite substantial research, a commercially viable vaccine for Schistosomiasis has not yet been developed, and this delay in vaccine availability continues to place the burden on pharmaceutical treatments. The absence of a preventive measure leaves communities reliant on drug-based interventions, which may not always be available or effective.

Additionally, the stigma surrounding Schistosomiasis in some regions, especially in rural areas, can delay diagnosis and treatment. Many people living in endemic areas may not seek treatment due to cultural or social barriers, or they may not recognize the symptoms of the disease. This delay in treatment increases the risk of complications and spread, further exacerbating the disease burden.

Lastly, inadequate healthcare infrastructure in many endemic regions, particularly in low-income countries, remains a significant challenge. Limited access to medical professionals, diagnostic tools, and adequate drug distribution systems can make it difficult to treat Schistosomiasis effectively, leading to long-term health issues for affected individuals and contributing to the spread of the disease.

Segmentation Analysis

The Drugs for Schistosomiasis market can be segmented based on type, application, and region. By type, the market is divided into monotherapies, combination therapies, and others. Monotherapies, particularly praziquantel, dominate the market due to their long-standing use and effectiveness in treating Schistosomiasis. However, combination therapies are expected to gain market share in the coming years, driven by the need to address drug resistance and improve treatment outcomes.

Regional segmentation plays a key role in shaping the market dynamics. The Drugs for Schistosomiasis market is dominated by regions such as Sub-Saharan Africa, Southeast Asia, and Latin America, where the prevalence of the disease is highest. North America and Europe, while not the primary regions for Schistosomiasis, are expected to see growth due to increased research funding and the development of novel drugs.

By Type

The Drugs for Schistosomiasis market can be categorized by type into monotherapies and combination therapies. Monotherapies, particularly praziquantel, are the most commonly used drugs for the treatment of Schistosomiasis. Praziquantel has proven to be highly effective in curing the disease by targeting the parasitic worms that cause Schistosomiasis. It has been the standard treatment for several decades, making it the most widely prescribed drug in the market.

However, due to the rise in drug resistance, there is a growing shift towards combination therapies. These therapies involve the use of multiple drugs that act on different stages of the parasite’s life cycle, reducing the risk of resistance and improving treatment outcomes. Combination therapies are gaining popularity as they offer a more effective approach to treating the disease, especially in areas where resistance to praziquantel is becoming a concern. The development of these therapies is expected to continue to evolve as pharmaceutical companies aim to address the challenges posed by drug resistance.

By Application

The market for Drugs for Schistosomiasis is also segmented by application into pediatric and adult treatments. The pediatric segment is a significant focus due to the high prevalence of Schistosomiasis among children, especially in regions where sanitation and access to clean water are limited. Many public health programs prioritize treating children to prevent long-term health complications caused by the disease, such as stunted growth, anemia, and impaired cognitive development.

The adult treatment segment remains important as well, as a significant number of adults in endemic regions suffer from Schistosomiasis. Adults in rural areas often lack access to healthcare, leading to delayed treatment and the spread of the disease. The treatment of adults is critical for controlling the disease in affected communities and preventing its transmission to children.

report_world_map

Request a Free sample    to learn more about this report.

Drugs For Schistosomiasis Market Regional Outlook

The regional outlook for the Drugs for Schistosomiasis market highlights a strong demand for treatments in endemic regions such as Sub-Saharan Africa, Southeast Asia, and Latin America. These areas experience the highest burden of the disease and have the greatest need for effective treatments. Governments, international organizations, and pharmaceutical companies are working to improve access to drugs in these regions, where healthcare infrastructure remains a challenge.

North America

In North America, the market for Schistosomiasis drugs is relatively small but growing due to increased research and development funding for neglected tropical diseases. While the disease is not as prevalent in North America, rising awareness and efforts to combat global health issues are driving demand for treatments and vaccines. Companies in North America are focusing on developing innovative drug solutions and participating in international collaborations to help combat Schistosomiasis worldwide.

Europe

Europe has a modest market for Drugs for Schistosomiasis, primarily driven by research and development activities aimed at finding new treatments for neglected tropical diseases. European pharmaceutical companies are at the forefront of innovation in Schistosomiasis drug development and are involved in public health initiatives in endemic regions. The European market is expected to see steady growth as global health organizations continue to prioritize Schistosomiasis as a public health issue.

Asia-Pacific

The Asia-Pacific region is another key market for Schistosomiasis treatments due to the high prevalence of the disease in countries such as China and India. Efforts to control Schistosomiasis in this region are supported by government initiatives and collaborations with international health organizations. The growing healthcare infrastructure in Asia-Pacific, coupled with increasing awareness, is expected to drive the demand for Schistosomiasis drugs in this region.

Middle East & Africa

In the Middle East and Africa, the market for Schistosomiasis drugs is primarily concentrated in Sub-Saharan Africa, where the disease burden is the highest. Efforts to combat Schistosomiasis in this region are supported by global health organizations and government programs. The growing focus on improving healthcare access and reducing the impact of neglected tropical diseases in this region is expected to boost market growth in the coming years.

List of Key Drugs For Schistosomiasis Companies Profiled

  • Merck
  • Bayer
  • Shin Poong
  • Taj Pharmaceuticals
  • Chandra Bhagat Pharma
  • EIPICO

COVID-19 Impacting Drugs For Schistosomiasis Market

The COVID-19 pandemic has had a significant impact on the global healthcare sector, including the Drugs for Schistosomiasis market. The pandemic has disrupted healthcare systems worldwide, particularly in developing countries where Schistosomiasis is most prevalent. Healthcare resources were diverted towards managing COVID-19, resulting in delays and disruptions in the distribution of essential medicines for neglected tropical diseases like Schistosomiasis. This delay in treatment availability has affected ongoing control efforts and the management of the disease in endemic areas.

Furthermore, travel restrictions and lockdown measures have limited the ability of international organizations, NGOs, and pharmaceutical companies to conduct fieldwork, supply chains have been interrupted, and access to medical facilities has been restricted. These disruptions have delayed drug administration campaigns and health screening activities in affected regions. However, as the global health focus shifts toward recovery, there are renewed efforts to strengthen healthcare systems and reinitiate Schistosomiasis treatment programs. The market is expected to recover gradually as global vaccination efforts progress and healthcare resources are restored to pre-pandemic levels.

Investment Analysis and Opportunities

The Drugs for Schistosomiasis market presents significant investment opportunities, particularly in regions where the disease burden remains high. Governments, non-governmental organizations (NGOs), and international health bodies are actively investing in the control and treatment of neglected tropical diseases, including Schistosomiasis. 

Pharmaceutical companies, especially those focusing on neglected tropical diseases, are encouraged to allocate more resources towards R&D for innovative drug solutions to combat drug resistance and improve treatment adherence. Investment in combination therapies, which target multiple stages of the parasite's life cycle, is gaining traction, as these therapies have the potential to overcome the limitations of existing monotherapies. 

Digital health technologies, such as mobile apps for monitoring treatment adherence, diagnostic tools, and telemedicine platforms, also offer promising investment opportunities. These innovations can improve diagnosis, patient management, and access to drugs, particularly in underserved regions. 

Recent Developments

  • The World Health Organization (WHO) has increased its efforts to combat Schistosomiasis through expanded drug distribution programs and advocacy for increased funding to control the disease in endemic regions.
  • In 2023, a collaboration between several global pharmaceutical companies and NGOs resulted in a new distribution initiative aimed at providing free praziquantel treatments to over 100 million people in sub-Saharan Africa.
  • Several clinical trials for new combination therapies have shown promising results, indicating that drugs targeting multiple stages of Schistosomiasis infection could soon be approved for use.
  • Researchers are actively exploring the potential of monoclonal antibodies as a new treatment option for Schistosomiasis, and early-stage trials have demonstrated some positive results.
  • A new mobile health application was launched in 2023 to help track patient treatment adherence and provide real-time diagnostic support in remote areas with limited healthcare infrastructure.
  • Public health campaigns and education efforts focused on Schistosomiasis awareness have increased in endemic regions, leading to better prevention and treatment uptake.

REPORT COVERAGE of Drugs For Schistosomiasis Market

This report provides a comprehensive analysis of the global Drugs for Schistosomiasis market, including current trends, market dynamics, segmentation, and regional outlook. It covers detailed insights into market drivers, restraints, and opportunities, providing a clear understanding of the factors influencing market growth. The report examines key market players, their strategies, and the competitive landscape, offering valuable information for stakeholders looking to enter or expand their presence in the market.

Key segments of the report include in-depth analysis by type, application, and region, providing an accurate and up-to-date picture of the market’s performance across various regions. It also highlights the impact of COVID-19 on market operations and discusses the future recovery and growth prospects. 

Additionally, the report explores the latest developments in Schistosomiasis treatment, including new drugs, technological advancements, and research breakthroughs. The market forecast provided in the report helps stakeholders anticipate future market trends and plan strategically for the coming years. Overall, the report offers an invaluable resource for those seeking detailed and actionable insights into the global Drugs for Schistosomiasis market.

NEW PRODUCTS

In recent years, the development of new products for the treatment of Schistosomiasis has gained significant momentum as pharmaceutical companies focus on addressing the challenges posed by drug resistance and improving treatment efficacy. One of the most notable new products is a combination therapy that targets multiple stages of the Schistosoma parasite's lifecycle. 

In addition to pharmaceutical advancements, new delivery systems are also being explored. For example, researchers are developing oral formulations with extended-release mechanisms to improve patient adherence, especially in pediatric and elderly populations. These formulations are designed to release the drug gradually over time, ensuring more consistent therapeutic levels and reducing the frequency of administration. 

Another significant product innovation is the use of digital health tools to improve diagnosis and treatment management. Mobile apps and telemedicine solutions are being introduced to help monitor patient progress and adherence to treatment regimens, especially in remote and underserved areas. These tools offer real-time support for patients and healthcare providers, ensuring better outcomes and increased access to Schistosomiasis treatments.

Drugs For Schistosomiasis Market Report Detail Scope and Segmentation
Report Coverage Report Details

By Applications Covered

S. intercalatum, S. mekongi, S. japonicum, S. mansoni, S. haematobium

By Type Covered

Oxamniquine, Praziquantel, Others

No. of Pages Covered

114

Forecast Period Covered

2024-2032

Growth Rate Covered

CAGR of 6.79% during the forecast period

Value Projection Covered

USD 150.41 million by 2032

Historical Data Available for

2019 to 2022

Region Covered

North America, Europe, Asia-Pacific, South America, Middle East, Africa

Countries Covered

U.S. ,Canada, Germany,U.K.,France, Japan , China , India, South Africa , Brazil

Frequently Asked Questions

  • What value is the Drugs For Schistosomiasis market expected to touch by 2032?

    The global Drugs For Schistosomiasis market is expected to reach USD 150.41 million by 2032.

  • What CAGR is the Drugs For Schistosomiasis market expected to exhibit by 2032?

    The Drugs For Schistosomiasis market is expected to exhibit a CAGR of 6.79% by 2032.

  • Which are the key players or most dominating companies functioning in the Drugs For Schistosomiasis market?

    Merck, Bayer, Shin Poong, Taj Pharmaceuticals, Chandra Bhagat Pharma, EIPICO

  • What was the value of the Drugs For Schistosomiasis market in 2023?

    In 2023, the Drugs For Schistosomiasis market value stood at USD 83.29 million.

What is included in this Sample?

  • * Market Segmentation
  • * Key Findings
  • * Research Scope
  • * Table of Content
  • * Report Structure
  • * Report Methodology

Download FREE Sample Report

man icon
Mail icon
+1
  • United States+1
  • Afghanistan (‫افغانستان‬‎)+93
  • Albania (Shqipëri)+355
  • Algeria (‫الجزائر‬‎)+213
  • American Samoa+1684
  • Andorra+376
  • Angola+244
  • Anguilla+1264
  • Antigua and Barbuda+1268
  • Argentina+54
  • Armenia (Հայաստան)+374
  • Aruba+297
  • Australia+61
  • Austria (Österreich)+43
  • Azerbaijan (Azərbaycan)+994
  • Bahamas+1242
  • Bahrain (‫البحرين‬‎)+973
  • Bangladesh (বাংলাদেশ)+880
  • Barbados+1246
  • Belarus (Беларусь)+375
  • Belgium (België)+32
  • Belize+501
  • Benin (Bénin)+229
  • Bermuda+1441
  • Bhutan (འབྲུག)+975
  • Bolivia+591
  • Bosnia and Herzegovina (Босна и Херцеговина)+387
  • Botswana+267
  • Brazil (Brasil)+55
  • British Indian Ocean Territory+246
  • British Virgin Islands+1284
  • Brunei+673
  • Bulgaria (България)+359
  • Burkina Faso+226
  • Burundi (Uburundi)+257
  • Cambodia (កម្ពុជា)+855
  • Cameroon (Cameroun)+237
  • Canada+1
  • Cape Verde (Kabu Verdi)+238
  • Caribbean Netherlands+599
  • Cayman Islands+1345
  • Central African Republic (République centrafricaine)+236
  • Chad (Tchad)+235
  • Chile+56
  • China (中国)+86
  • Christmas Island+61
  • Cocos (Keeling) Islands+61
  • Colombia+57
  • Comoros (‫جزر القمر‬‎)+269
  • Congo (DRC) (Jamhuri ya Kidemokrasia ya Kongo)+243
  • Congo (Republic) (Congo-Brazzaville)+242
  • Cook Islands+682
  • Costa Rica+506
  • Côte d’Ivoire+225
  • Croatia (Hrvatska)+385
  • Cuba+53
  • Curaçao+599
  • Cyprus (Κύπρος)+357
  • Czech Republic (Česká republika)+420
  • Denmark (Danmark)+45
  • Djibouti+253
  • Dominica+1767
  • Dominican Republic (República Dominicana)+1
  • Ecuador+593
  • Egypt (‫مصر‬‎)+20
  • El Salvador+503
  • Equatorial Guinea (Guinea Ecuatorial)+240
  • Eritrea+291
  • Estonia (Eesti)+372
  • Ethiopia+251
  • Falkland Islands (Islas Malvinas)+500
  • Faroe Islands (Føroyar)+298
  • Fiji+679
  • Finland (Suomi)+358
  • France+33
  • French Guiana (Guyane française)+594
  • French Polynesia (Polynésie française)+689
  • Gabon+241
  • Gambia+220
  • Georgia (საქართველო)+995
  • Germany (Deutschland)+49
  • Ghana (Gaana)+233
  • Gibraltar+350
  • Greece (Ελλάδα)+30
  • Greenland (Kalaallit Nunaat)+299
  • Grenada+1473
  • Guadeloupe+590
  • Guam+1671
  • Guatemala+502
  • Guernsey+44
  • Guinea (Guinée)+224
  • Guinea-Bissau (Guiné Bissau)+245
  • Guyana+592
  • Haiti+509
  • Honduras+504
  • Hong Kong (香港)+852
  • Hungary (Magyarország)+36
  • Iceland (Ísland)+354
  • India (भारत)+91
  • Indonesia+62
  • Iran (‫ایران‬‎)+98
  • Iraq (‫العراق‬‎)+964
  • Ireland+353
  • Isle of Man+44
  • Israel (‫ישראל‬‎)+972
  • Italy (Italia)+39
  • Jamaica+1
  • Japan (日本)+81
  • Jersey+44
  • Jordan (‫الأردن‬‎)+962
  • Kazakhstan (Казахстан)+7
  • Kenya+254
  • Kiribati+686
  • Kosovo+383
  • Kuwait (‫الكويت‬‎)+965
  • Kyrgyzstan (Кыргызстан)+996
  • Laos (ລາວ)+856
  • Latvia (Latvija)+371
  • Lebanon (‫لبنان‬‎)+961
  • Lesotho+266
  • Liberia+231
  • Libya (‫ليبيا‬‎)+218
  • Liechtenstein+423
  • Lithuania (Lietuva)+370
  • Luxembourg+352
  • Macau (澳門)+853
  • Macedonia (FYROM) (Македонија)+389
  • Madagascar (Madagasikara)+261
  • Malawi+265
  • Malaysia+60
  • Maldives+960
  • Mali+223
  • Malta+356
  • Marshall Islands+692
  • Martinique+596
  • Mauritania (‫موريتانيا‬‎)+222
  • Mauritius (Moris)+230
  • Mayotte+262
  • Mexico (México)+52
  • Micronesia+691
  • Moldova (Republica Moldova)+373
  • Monaco+377
  • Mongolia (Монгол)+976
  • Montenegro (Crna Gora)+382
  • Montserrat+1664
  • Morocco (‫المغرب‬‎)+212
  • Mozambique (Moçambique)+258
  • Myanmar (Burma) (မြန်မာ)+95
  • Namibia (Namibië)+264
  • Nauru+674
  • Nepal (नेपाल)+977
  • Netherlands (Nederland)+31
  • New Caledonia (Nouvelle-Calédonie)+687
  • New Zealand+64
  • Nicaragua+505
  • Niger (Nijar)+227
  • Nigeria+234
  • Niue+683
  • Norfolk Island+672
  • North Korea (조선 민주주의 인민 공화국)+850
  • Northern Mariana Islands+1670
  • Norway (Norge)+47
  • Oman (‫عُمان‬‎)+968
  • Pakistan (‫پاکستان‬‎)+92
  • Palau+680
  • Palestine (‫فلسطين‬‎)+970
  • Panama (Panamá)+507
  • Papua New Guinea+675
  • Paraguay+595
  • Peru (Perú)+51
  • Philippines+63
  • Poland (Polska)+48
  • Portugal+351
  • Puerto Rico+1
  • Qatar (‫قطر‬‎)+974
  • Réunion (La Réunion)+262
  • Romania (România)+40
  • Russia (Россия)+7
  • Rwanda+250
  • Saint Barthélemy+590
  • Saint Helena+290
  • Saint Kitts and Nevis+1869
  • Saint Lucia+1758
  • Saint Martin (Saint-Martin (partie française))+590
  • Saint Pierre and Miquelon (Saint-Pierre-et-Miquelon)+508
  • Saint Vincent and the Grenadines+1784
  • Samoa+685
  • San Marino+378
  • São Tomé and Príncipe (São Tomé e Príncipe)+239
  • Saudi Arabia (‫المملكة العربية السعودية‬‎)+966
  • Senegal (Sénégal)+221
  • Serbia (Србија)+381
  • Seychelles+248
  • Sierra Leone+232
  • Singapore+65
  • Sint Maarten+1721
  • Slovakia (Slovensko)+421
  • Slovenia (Slovenija)+386
  • Solomon Islands+677
  • Somalia (Soomaaliya)+252
  • South Africa+27
  • South Korea (대한민국)+82
  • South Sudan (‫جنوب السودان‬‎)+211
  • Spain (España)+34
  • Sri Lanka (ශ්‍රී ලංකාව)+94
  • Sudan (‫السودان‬‎)+249
  • Suriname+597
  • Svalbard and Jan Mayen+47
  • Swaziland+268
  • Sweden (Sverige)+46
  • Switzerland (Schweiz)+41
  • Syria (‫سوريا‬‎)+963
  • Taiwan (台灣)+886
  • Tajikistan+992
  • Tanzania+255
  • Thailand (ไทย)+66
  • Timor-Leste+670
  • Togo+228
  • Tokelau+690
  • Tonga+676
  • Trinidad and Tobago+1868
  • Tunisia (‫تونس‬‎)+216
  • Turkey (Türkiye)+90
  • Turkmenistan+993
  • Turks and Caicos Islands+1649
  • Tuvalu+688
  • U.S. Virgin Islands+1340
  • Uganda+256
  • Ukraine (Україна)+380
  • United Arab Emirates (‫الإمارات العربية المتحدة‬‎)+971
  • United Kingdom+44
  • United States+1
  • Uruguay+598
  • Uzbekistan (Oʻzbekiston)+998
  • Vanuatu+678
  • Vatican City (Città del Vaticano)+39
  • Venezuela+58
  • Vietnam (Việt Nam)+84
  • Wallis and Futuna (Wallis-et-Futuna)+681
  • Western Sahara (‫الصحراء الغربية‬‎)+212
  • Yemen (‫اليمن‬‎)+967
  • Zambia+260
  • Zimbabwe+263
  • Åland Islands+358
Captcha refresh
loader
Insights Image

Request A FREE Sample PDF PDF

Man
Mail
Captcha refresh
loader

Join Our Newsletter

Get the latest news on our products, services, discounts, and special offers delivered directly to your mailbox.

footer logo

Global Growth Insights
Office No.- B, 2nd Floor, Icon Tower, Baner-Mhalunge Road, Baner, Pune 411045, Maharashtra, India.

Useful Links

  • HOME
  • ABOUT US
  • TERMS OF SERVICE
  • PRIVACY POLICY

Our Contacts

Toll-Free Numbers:
US : +1 (855) 467-7775
UK : +44 8085 022397

Email:
 sales@globalgrowthinsights.com

Connect With Us

Twitter

footer logo

© Copyright 2024 Global Growth Insights. All Rights Reserved | Powered by Absolute Reports.
×
We use cookies.

to enhance your experience.

More info.
  • Industries
    •   Information & Technology
    •   Healthcare
    •   Machinery & Equipment
    •   Automotive & Transportation
    •   Food & Beverages
    •   Energy & Power
    •   Aerospace & Defense
    •   Agriculture
    •   Chemicals & Materials
    •   Architecture
    •   Consumer Goods
  • Blogs
  • About
  • Contact